Translated with AI
On November 19, 2025, the Therapeutic Goods Administration (TGA) released the updated guidance “Complying with the Essential Principles”, effective immediately. The document defines the requirements for market entry in Australia under the Therapeutic Goods (Medical Devices) Regulations 2002, elevating the interpretative standards for the entire product lifecycle.
Across 15 Essential Principles (EP), the guidance covers the requirements for the design, production, and distribution of safe and effective Medical Devices. The update introduces more specific details and clarifications without altering the regulatory framework; the most significant developments concern Principle 13 (UDI) and Cybersecurity (EP 12).
Overview of the 15 Essential Principles (EP)
- EP 1: Use of Medical Devices not to compromise health and safety
Requires devices to be designed and produced so they will not compromise the health and safety of patients, users, or others. The update emphasizes a structured Risk Management approach, extending from the entire lifecycle (design and production) to decommissioning, integrating literature analysis and post-market experience. - EP 2: Design and construction
Set high standards and emphasizes (Total Product Lifecycle) management through the quality system. This approach enables continuous improvement processes and incremental updates aligned with the State of the Art. - EP 3: Intended performance
Ensures reliable operation in normal situations; details have been added regarding verification for real-world scenarios and potential malfunctions. - EP 4: Durability
Guarantees that performance remains unaffected throughout the service life. The novelty lies in the required in-depth analysis of material degradation and rigorous validation of storage and transport conditions (shelf-life testing). - EP 5: Transport and storage
The main change involves moving from theoretical resistance forecasts to empirical validation and logistical stress-testing. The guidance requires that performance is not altered by extreme environmental factors during distribution. - EP 6: Benefit/Risk analysis
The guidance now requires an analytical distinction: each individual variant or model must have its own documentation demonstrating that specific benefits outweigh residual risks. - EP 7: Chemical, physical and biological properties
Ensures material safety through high biocompatibility standards. For animal-origin components, formal supply chain monitoring is now required to ensure the absence of toxic substances or harmful residues. - EP 8: Infection and contamination risk
Guarantees the microbiological purity of the device. The update introduces specific clauses (8.10/8.11) requiring more rigorous protocols to validate sterilization cycles and viral reduction. - EP 9: Environmental interactions
Ensures the device is isolated from external perturbations. The requirement has been refined to focus on the robustness of the protective enclosure against environmental agents and interference. - EP 10: Measuring functions
Guarantees constant and verifiable accuracy. The novelty lies in the expansion of validation examples and more analytical stability testing. - EP 11: Protection against radiation
Binds the device to emission containment. The update introduces more precise specifications for shielding systems to maximize the safety of users and patients. - EP 12: Electronic systems and Cybersecurity
Extensively updated with mandatory Cybersecurity requirements (EP 12.1). In addition to electrical safety, it imposes criteria for software resilience, malware protection, and data privacy. - EP 13: Labelling, Instructions and Traceability (UDI)
Represents the most significant update with the introduction of new clauses 13.5 and 13.6. The regulations integrate the UDI (Unique Device Identification) system, distinguishing between Device Identifier (DI) and Production Identifier (PI), with obligations for direct marking and data submission to the AusUDID database. - EP 14: Clinical evidence
Strengthens the obligation to provide clinical data proportionate to the risk class. The key change is the enhancement of Post-Market Clinical Follow-up, transforming evidence collection into continuous monitoring throughout the lifecycle. - EP 15: In Vitro Diagnostic (IVD) Medical Devices
Introduces more rigorous standards for the validation of analytical sensitivity and specificity, imposing more detailed metrological traceability of results.
Conclusion: impact of the new guidelines
The evolution of TGA guidelines points toward increasingly stringent requirements across the product lifecycle. A key example is the EP 13 (UDI) update, with timelines established by the Therapeutic Goods (Medical Devices—Unique Device Identification) Regulations 2023, which sets the compliance deadline of July 1, 2026 for Class III and Class IIb devices (including labelling and AusUDID data submission). In this scenario, compliance is a dynamic process requiring constant alignment of the QMS and Technical File: from design to production (EP 8 sterility, EP 12 Cybersecurity) to post-market surveillance (EP 14). To ensure a safe market presence, a gap analysis is recommended to verify document robustness against these updated standards.
>>> Thema provides the necessary support to interpret these complexities and maintain Compliance.
